We are live on ! Find out more
CRL icon

Charles River Laboratories

627 hedge funds and large institutions have $10.3B invested in Charles River Laboratories in 2024 Q3 according to their latest regulatory filings, with 66 funds opening new positions, 204 increasing their positions, 273 reducing their positions, and 97 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.76% less ownership

Funds ownership: 101.73%100.97% (-0.76%)

5% less capital invested

Capital invested by funds: $10.8B → $10.3B (-$568M)

6% less funds holding

Funds holding: 664627 (-37)

25% less funds holding in top 10

Funds holding in top 10: 86 (-2)

25% less repeat investments, than reductions

Existing positions increased: 204 | Existing positions reduced: 273

32% less first-time investments, than exits

New positions opened: 66 | Existing positions closed: 97

38% less call options, than puts

Call options by funds: $59M | Put options by funds: $94.8M

Holders
627
Holders Change
-37
Holders Change %
-5.57%
% of All Funds
9%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.09%
New
66
Increased
204
Reduced
273
Closed
97
Calls
$59M
Puts
$94.8M
Net Calls
-$35.8M
Net Calls Change
-$26.6M
Name Holding Trade Value Shares
Change
Change in
Stake
Aviva
401
Aviva
United Kingdom
$381K -$1.71M -8,241 -81%
GLA
402
Great Lakes Advisors
Illinois
$380K -$488K -2,347 -55%
KPWS
403
Kestra Private Wealth Services
Texas
$376K +$3.95K +19 +1%
WA
404
Wealth Alliance
New York
$375K +$7.69K +37 +2%
MCC
405
Malaga Cove Capital
California
$374K -$406K -1,955 -51%
CIP
406
Cornerstone Investment Partners
Georgia
$369K +$416 +2 +0.1%
MPWT
407
MassMutual Private Wealth & Trust
Connecticut
$363K +$16.4K +79 +4%
SWP
408
Stratos Wealth Partners
Ohio
$362K -$72.3K -348 -16%
MIA
409
MainStreet Investment Advisors
Illinois
$362K -$38.7K -186 -9%
AFG
410
Atomi Financial Group
New York
$361K -$17K -82 -4%
AA
411
Axiom Advisory
California
$359K +$5.61K +27 +2%
CCM
412
Coldstream Capital Management
Washington
$356K -$17.9K -86 -5%
BMCM
413
Bryn Mawr Capital Management
Pennsylvania
$356K
MC
414
Moors & Cabot
Massachusetts
$356K -$39.5K -190 -10%
YMRC
415
Yorktown Management & Research Company
Virginia
$355K
PAG
416
Private Advisor Group
New Jersey
$348K -$43.9K -211 -11%
IMCOOI
417
Investment Management Corp of Ontario (IMCO)
Canada
$340K +$125K +600 +53%
WR
418
WD Rutherford
Oregon
$338K -$2.48M -11,914 -87%
HFO
419
Heritage Family Offices
Arizona
$335K +$1.87K +9 +0.5%
TWC
420
TD Waterhouse Canada
Ontario, Canada
$332K +$62.6K +301 +21%
William Blair & Company
421
William Blair & Company
Illinois
$330K +$831 +4 +0.2%
LNWWM
422
Laird Norton Wetherby Wealth Management
California
$329K -$7.48K -36 -2%
MGP
423
Metis Global Partners
California
$325K +$4.36K +21 +1%
NMIMC
424
Northwestern Mutual Investment Management Company
Wisconsin
$322K -$623 -3 -0.2%
SPIO
425
Seven Post Investment Office
California
$320K

CRL Hedge Fund Activity: Q3 2024 in Review

627 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q3 2024, worth a combined $10.3B — down 5.2% from $10.8B a quarter earlier.

Sellers outnumbered buyers: 97 funds closed out of CRL and 66 opened new positions — a net loss of 31 holders — while 273 trimmed existing stakes and 204 added.

The largest buyer was Wellington Management Group, adding an estimated $777M. The largest seller was BlackRock, cutting an estimated $177M.

  • 627 institutional investors held Charles River Laboratories (CRL) as of Q3 2024, down from 664 in Q2 2024.
  • Funds reported $10.3B of Charles River Laboratories stock for Q3 2024, down 5.2% quarter-over-quarter.
  • 66 funds opened new Charles River Laboratories positions in Q3 2024 and 97 closed out, a net change of -31 holders.
  • The largest Charles River Laboratories buyer in Q3 2024 was Wellington Management Group, an estimated $777M added.
  • The largest Charles River Laboratories seller in Q3 2024 was BlackRock, an estimated $177M sold.

Based on aggregated 13F filings for Q3 2024.